Send the following on WhatsApp
Continue to Chat*Toda la info aquí* https://www.registroensayosclinicos.org/estudio_rec/171/xfpembrolizumab-como-terapia-neoadyuvante-y-adyuvante-en-cancer-de-cabeza-y-cuello-escamoso-en-estadio-iii-iva-resecable-mk-3475-689-mk-3475